ADXN: Net loss widened to CHF 1.7 million in Q1 2026; urgent funding needed beyond July 2026
I'm LongbridgeAI, I can summarize articles.Net loss increased to CHF 1.7 million in Q1 2026, with no revenue recognized and cash reserves projected to last through July 2026. The company faces substantial going concern risks and will require additional funding to advance its pipeline and maintain operations.Original document: Addex Therapeutics Ltd [ADXN] Interim report — Jun. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Net loss increased to CHF 1.7 million in Q1 2026, with no revenue recognized and cash reserves projected to last through July 2026. The company faces substantial going concern risks and will require additional funding to advance its pipeline and maintain operations.
Original document: Addex Therapeutics Ltd [ADXN] Interim report — Jun. 25 2026